Biogen Idec Inc BIIB:NASDAQ

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
342.58 -3.26   -0.94%0.00%700,0541.1M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 8/20/2014

Latest News Headlines for Biogen Idec Inc

Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, August 20, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.

Biogen Idec's PLEGRIDY(TM)(Peginterferon Beta-1a) -2-

(3) Multiple Sclerosis International Federation, Atlas of MS 2013. Epidemiology of MS. Page 8. Date Accessed: May 14, 2014. http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?f=1

Biogen Idec's PLEGRIDY(TM)(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis

- Reduces Relapses, Disability Progression and Brain Lesions with a Favorable Safety Profile - - Only Pegylated Interferon in MS, Dosed Once Every Two Weeks -- - Complements Biogen Idec's Industry-Leading Portfolio of MS Products --

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

http://www.biogenidec.com/

Loading...
Bid/SizeAsk/Size
-- / ---- / --
Price OpenPrevious Close
343.68342.58
Day HighDay Low
----
52wk High/Date52wk Low/Date
358.89 / 3/19/2014203.55 / 8/21/2013
% off 52wk High% off 52wk Low
(4.54)%68.30%
Beta (5 Yr)Market Capitalization
1.280.9B Large Cap
Shares OutstandingVolatility Avg
236.1M36.92
EPS(TTM)P/E Ratio
9.0038.1
Dividend AnnouncementDividend Yield
--0.00%
Ex-DateDate of Record
----
PayablePayable Date
0.00 - ----

Last Trade as of 8/20/2014 4:00 PM ET

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

Peers 
BIIB
Biogen Idec Inc
22.54%
Johnson & Johnson
12.69%
Pfizer Inc.
-5.68%
Merck & Co., Inc.
18.84%
AbbVie Inc
4.26%
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.71%
Pfizer Inc.
3.60%
Merck & Co., Inc.
2.96%
AbbVie Inc
3.05%
BIIB
Biogen Idec Inc
-0.94%
Johnson & Johnson
0.24%
Pfizer Inc.
-0.17%
Merck & Co., Inc.
0.97%
AbbVie Inc
-0.42%
Compare these stocks